

EUBREAST NETWORK

SEPTEMBER 2026



Maggie Banys-Paluchowski, Melissa Neubacher, Natalia Krawczyk

BREAKING NEWS!!!!

We are thrilled to announce that the **AXSANA/EUBREAST 3 (R)** study paper, "More versus less invasive axillary staging after NACT in breast cancer patients converting from clinically positive to negative lymph nodes (AXSANA/EUBREAST 3 (R)): an international prospective cohort study," has been accepted for publication in **The Lancet Oncology!**

This is a truly outstanding achievement and an important milestone for the AXSANA Study and the EUBREAST Network. Congratulations to the authors as well as everyone who has contributed to the Study! Your dedication, collaboration, and commitment have made this achievement possible. And, last, but certainly not least, a heartfelt thanks to our sponsors and, above all, our patients, whose generosity, trust, and participation made this research possible.


We are incredibly proud of our team's achievement and look forward to sharing the published paper soon! 🎉

In addition to the great news above, in 2026, EUBREAST has successfully launched **GRAMAREG/EUBREAST 15 (R)**, and we are delighted to announce that two new studies—**INSPIRE** and **SLYMT/AXSANA 3**—have recently been approved. Moreover, a timely and important international registry is in development that we look forward to sharing with you over the next months.

We truly appreciate your continued enthusiasm and commitment to EUBREAST and we look forward to reaching many more milestones together!

Prof Thorsten Kuehn, Prof Oreste Gentilini, and
The EUBREAST Team

IN FOCUS: ASCO 2026



The **AXSANA/EUBREAST 3** study presented new findings on the prediction of axillary pathologic complete response following neoadjuvant systemic therapy. These results bring us one step closer to identifying patients who may safely benefit from less extensive axillary surgery while maintaining oncologic safety. Congratulations to Prof Maggie Banys-Paluchowski for her superb presentation ([overview here](#)).

EUBREAST EDUCATIONAL WEBINARS 2026: JOIN US

The EUBREAST Educational Series is back! **Please join us for the upcoming two live webinars** with international experts and interactive discussions. All our previous webinars are **available on demand**. These sessions would not be possible without the generosity of our sponsors: **MSD (Main Sponsor)** and **Sirius Medical**.

THE EUBREAST NETWORK: WEBINARS 2026	
SAVE THE DATES MORE DETAILS AVAILABLE ON OUR WEBSITE https://www.eubreast.org/eubreast-23-e-eubreast-educational-program-2026/	
EUBREAST EDUCATIONAL SERIES • 18 JUNE 2026 - 18.00-19.00 CEST Challenges in primary systemic therapy and axillary treatment in metastatic and rare triple negative disease (available on-demand) • 10 SEPTEMBER 2026 - 18.00-19.00 CEST High-risk ER-positive breast cancer: Surgery or systemic therapy first • 19 NOVEMBER 2026 - 18.00-19.00 CET Can we reduce the surgical extent (breast and axilla) after primary systemic therapy in patients with inflammatory breast cancer?	
 Main Sponsor	 Co-Sponsor
Free-of-charge, registration required www.eubreast.org	

PUBLICATIONS, PRIZES, AND PRESENTATIONS

PUBLICATIONS:

Pre-Pectoral Breast Reconstruction after Mastectomy: Current Evidence, Knowledge Gaps, and Rationale for the I-PREPARE EUBREAST-11R Trial (R. Di Micco, L. Scardina), Breast Care, June 2026

Marking Techniques for Target Lymph Nodes in Node-Positive Breast Cancer Treated With Neoadjuvant Therapy in the AXSANA/EUBREAST-03/AGO-B-053 Study (M Banys-Paluchowski, S. Hartmann, J. de Boniface), Journal of Clinical Oncology, January 2026

EUBREAST Supported: Local management of second ipsilateral breast cancer events after primary breast-conserving therapy: an international Delphi consensus (Jean-Michel Hannoun-Levi et al.), Lancet Oncology, June 2026

PRIZES:

German Senology Conference: Melissa Neubacher from University Hospital Düsseldorf received the Florence Nightingale Prize for the EUBREAST international survey on granulomatous mastitis. Senior author, Natalia Krawczyk



Geeta Kadayaprath, Walter Weber, Judy Boughey, Maggie Banys-Paluchowski, Jana de Boniface, Nikolas Tauber

CONFERENCE PRESENTATIONS:

"From Grey Zones to Black and White in Breast Cancer" Conference 2026, New Delhi, IN

17th annual AWOgyn Conference 2026: Maggie Banys-Paluchowski, Congress President, presented MELODY. Nikolas Tauber chaired "career options for young doctors". Natalia Krawczyk chaired a session where Steffi Hartmann presented AXSANA and Kristina Veselinović presented I-PREPARE.

24th National Congress of Surgery, Antalya, TR
SGGG 2026 Jahreskongress, June 2026, CH
AG Senologie Webinar Series: Swiss participation in EUBREAST, July 2026, Maria Luisa Gasparri

Of special note: Executive member, Maria-Luisa Gasparri, proudly launched **GO WINNeRS - Women in Research, Gynecology & Obstetrics**, Lugano, CH.

collaborating
associations:



AGO-B
BREAST STUDY GROUP

**ONCOPLASTIC
BREAST CONSORTIUM**

**IBRA
NET**

AWOgyn

SENATURK
SENOLUJİ AKADEMİ

KBCS
KBCSG

**THE AMERICAN SOCIETY OF
Breast Surgeons**

OGGO

KBCS

EUBREAST NETWORK


SEPTEMBER 2026

ACTIVE EUBREAST STUDIES

- **GBG 104/EUBREAST 1 (R)** concluded recruitment on 31 December 2024 with over 400 patients. The data follow-up is ongoing and primary and secondary outcome data are expected for Q1/2028. (Enrollment Completed).
- **AXSANA/EUBREAST 3 (R)** recruited over 7000 patients between June 2020 and December 2025. It then continued as an unrestricted registry, AXSANA Plus, with over 7500 patients. Recently, new amendments to the protocol have been introduced to maximize the scientific value of the study by leveraging the data being collected across the nearly 300 participating international sites. Ultimately, these changes will strengthen the evidence generated by AXSANA/AXSANAPlus and help translate the findings into improved treatment strategies for our patients. (Accepting New Sites) Axsana@eubreast.com.
- **MELODY/EUBREAST 4 (R)** is the largest study worldwide on localization technique for non-palpable breast cancer. 223 study sites are currently open in 28 countries. With more than 12,000 patients enrolled, the study is progressing according to schedule. Please note that the wire cohort has been closed. (Accepting New Sites) melody@eubreast.com
- **SerMa/EUBREAST 5 (R)** Site initiation has been completed at 31 international participating centers within the EUBREAST network. Patient recruitment is ongoing. The study continues to welcome additional international centers to participate in recruitment and contribute to the planned target accrual of 2,200 participants. (Accepting New Sites)
- **I-PREPARE/EUBREAST 11 (R)** As of July 2026, 688 patients have been enrolled from 29 active sites from 11 countries worldwide with another 20 centers which have received or are waiting for EC/final approval. The study protocol was amended this year: recruitment will remain open until December 2027 in order to reach the planned recruitment target. For more info: goldman@eubreast.com (No Longer Accepting New Sites)
- **GRAMAREG/EUBREAST 15 (R)**, a non-interventional cohort study for patients with idiopathic granulomatous mastitis, has started recruitment in Germany and has received interest from sites in over 20 countries worldwide.. If you are interested in participating please contact gramareg@eubreast.org. (Accepting New Sites)
- **Neo-ACT/EUBREAST 16 (R)** is international randomized trial test the hypothesis that a remote physical exercise intervention via a mobile application improves pathological complete response rates in patients with breast cancer receiving preoperative systemic treatment. 432 patients have now been randomized from Sweden, Finland, Germany and Australia. Ireland will start in August. You can find more information about this [study here](#).
- **PROBAMUS/EUBREAST 18 (R)** We are pleased to announce that this registry is now open for both the retrospective and prospective recruitment of patients with occult primary breast cancer with axillary metastasis. For more information, please contact the Promoter/PI at marialuisa.gasparri@eoc.ch.
- **SLYMT-AXSANA 3 / EUBREAST 24 (R)** A randomized trial on Sentinel Lymph Node Biopsy versus Targeted Axillary Dissection in patients with initial nodal involvement converted to negative status after primary systemic treatment was recently approved by the swiss Ethic Commission and will be open soon. For additional information, please contact the Promoter/PI marialuisa.gasparri@eoc.ch.
- **INSPIRE-AXSANA 3 / EUBREAST 25 (R)** is a research program evaluating de-escalation of surgery in inflammatory breast cancer (IBC). Analysis of 3,539 patients demonstrated that IBC status was not independently associated with overall survival. The results are currently being validated in the German Cancer Registry Consortium and will be complemented by prospective data from the newly established IBC cohort within the international AXSANA study. (Study starting Q4)

EUBREAST SUPPORTED


- **PartBreCon-Pro**, an EUBREAST and ABS-supported international prospective study of partial breast reconstruction using chest wall perforator flaps following breast-conserving surgery, has enrolled 1100+ patients from 55+ active global sites. Another 50+ sites have expressed interest. It is open to new centres (until June 2028). For more information: partbrecon.pros@gmail.com



We kindly remind all AXSANA and MELODY Study PIs and Teams to support the ongoing data-cleaning efforts. Each enrolled patient with a complete, high-quality dataset helps strengthen the scientific value of these studies and ensure the reliability of our results. To this regard, we would also like to thank our excellent team of data-monitors for their support.

BEHIND THE SCENES

We are delighted to present our new office staff who work tirelessly to ensure the success of the EUBREAST Studies:



Ubeydullah Beykoz, Clinical Trial Associate, is specialized in data management. He joined the EUBREAST Team after obtaining an MS in Biotechnology.

Stefanie Sprejz, Clinical Research Associate, has joined EUBREAST after working for a CDMO for two years. She holds an MS in Technical Biology and has experience as a Clinical Project Manager.



BREASTANBUL 2026

Join EUBREAST in Istanbul this October!

EUBREAST is honored to be presenting three awards for:

- two surgical papers - oral presentation
- one surgical poster presentation

Each award category will have its own jury members, and all awards will be presented to the awardees during the closing ceremony on 10 October 2026 Saturday at 6:45 PM

Learn more about Breastanbul 2026:
<https://breastanbul2026.com/>